Table 3.
Response to first-line treatments following distant metastasis after failure of adjuvant BRAF/MEK-directed targeted therapy
| Single-agent CPI | Ipi+nivo | BRAF/MEKi | |
| N | 13 | 29 | 17 |
| Recurred ON TT | 3 (23.0%) | 11 (37.9%) | 3 (17.6%) |
| Recurred OFF TT | 10 (69.9%) | 18 (62.1%) | 14 (82.4%) |
| Median follow-up | 40 months (25.1–54.9) | 24 months (14.6–33.4) | 24 months (15.7–24.3) |
| rwTRR, N (%)† | |||
| Total | 1/13 (7.7%) | 9/21 (42.9%) | 1/11 (9.1%) |
| Recurred ON TT | 1/3 (33.3%) | 3/8 (37.5%) | 0/3 |
| Recurred OFF TT | 0/10 | 6/13 (46.2%) | 1/8 (12.5%) |
| Tumor progression, N (%) | 8/13 (61.2%) | 12/21 (57.1%) | 11/17 (64.7%) |
| Median PFS (95% CI) | 5 months (0 to 12.9) | NR (NA) | 3 months (0 to 6.2) |
| Median OS* (95% CI) | 26 months (NA) | NR | 9 months (4.1 to 14.0) |
Response rates to 1L systemic therapy following DM were deemed assessable if patients did not receive any prior systemic treatments for metastatic stage, had measurable disease for assessment and underwent radiological and clinical response assessment.
*Overall survival was calculated from the start of 1L therapy.
†Response assessments for 1L therapy upon adjuvant TT failure were available for 45 patients (13 for single-agent CPI; 21 for ipi+nivo and 11 for BRAF/MEKi therapy).
CPI, checkpoint inhibitor; DM, distant metastasis; NA, not available; NR, not reported; OS, overall survival; PFS, progression-free survival; rwTRR, real-world tumor response rate; TT, targeted therapy.